Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

3.090 USD +0.040 (+1.31%)
Official Closing Price Updated: 4:36 PM EST, Nov 27, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200,400
Open 3.070
Bid (Size) 3.060 (8)
Ask (Size) 3.150 (14)
Prev. Close 3.050
Today's Range 3.050 - 3.100
52wk Range 0.2310 - 7.030
Shares Outstanding 13,896,926
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Diamond Equity Research 2020 Virtual Emerging Growth Invitational
From ACCESSWIRE
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Diamond Equity Research Emerging Growth Invitational
From InvestorBrandNetwork

Performance

YTD
+896.77%
+896.77%
1 Month
-12.46%
-12.46%
3 Month
-21.97%
-21.97%
6 Month
+9.19%
+9.19%
1 Year
+1044.44%
+1044.44%

More News

Read More
Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1
From Business Wire News Releases
InvestorNewsBreaks – Benzinga Launches Global Small Cap Conference Series; First Event Slated for December
From InvestorBrandNetwork
Genprex to Participate in Panel at Life Sciences Summit on November 17
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Life Sciences Summit Panel
From InvestorBrandNetwork
Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Scientific Advisory Board with Strategic Appointment
From InvestorBrandNetwork
Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Launch of New Branding for Upcoming Combination Clinical Trials
From InvestorBrandNetwork
Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]